iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Lupin receives USFDA approval for Darunavir Tablets

9 Oct 2022 , 01:34 AM

Lupin announced that it has received approval from the United States Food and Drug Administration US FDA for its Abbreviated New Drug Application ANDA for Darunavir Tablets 600 mg and 800 mg a generic equivalent of Prezista Tablets of Janssen Products LP Lupin is the exclusive first filer for 800 mg tablets and is eligible for 180-day exclusivity Lupin will also potentially have shared 180-day exclusivity on the 600 mg tablets The product will be manufactured at Lupins facility in Nagpur India Darunavir Tablets 600 mg and 800 mg RLD Prezista had estimated annual sales of USD 343 million in the US IQVIA MAT June 2022

Related Tags

  • Announcements
  • BSE
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.